Contact VaccineNation
MOST POPULAR THIS MONTH
Report: investigating vaccine manufacturing in Africa
We know from before and during the COVID-19 pandemic that Africa’s demand for vaccines exceeds its local supply: 99% of vaccines administered on the continent are imported. The pandemic highlighted an existing need, but did it also galvanise action to establish...
COVID-19 vaccines and unexpected vaginal bleeding
Although insufficient attention has been directed towards the effects of vaccination on menstrual experiences, a study published in Science Advances in September 2023 presents research into the link between COVID-19 vaccination and “unexpected vaginal bleeding” in...
Gritstone bio awarded BARDA contract for COVID-19 study
In September 2023 Gritstone bio announced that is has been awarded a contract by BARDA to conduct a Phase IIb comparative study that will evaluate the company’s self-amplifying mRNA (samRNA) vaccine candidate, targeting COVID-19. The agreement is valued at up to $433...
Revital gets Pre-Qualification: early activation AD syringe
In September 2023 Revital Healthcare announced a “historic milestone in African manufacturing excellence”. The company was awarded Pre-Qualification (PQ) status by WHO in July 2023 for its early activation auto-disable (AD) syringe in Africa. This marks more than 10...
Genomic surveillance strategies: WHO’s step-by-step guide
In September 2023 WHO shared Considerations for developing a national genomic surveillance strategy or action plan for pathogens with pandemic and epidemic potential to support countries in the development of genomic surveillance strategies. This publication seeks to...
Vaccine start-ups return to the World Vaccine Congress!
In the last few weeks before the World Vaccine Congress in Barcelona, our start-up zone is reaching capacity! This week we are pleased to present another set of organisations that have already secured their spaces in the zone. To see previous introductions head over...
Cambridge shares further antigen technology success
The University of Cambridge announced in September 2023 that a vaccine antigen technology developed in collaboration with spin-out DIOSynVax in early 2020 demonstrated protection against all known variants of SARS-CoV-2 and other major coronaviruses. With a paper...
UKHSA and CSL Seqirus partnership: flu pandemic preparation
In September the UKHSA announced an agreed deal for “millions of life-saving vaccines” has been signed with CSL Seqirus. The advance purchase agreement (APA) ensures that CSL Seqirus is “on standby” to produce over 100 million influenza vaccines if an influenza...
